Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc. is a biopharmaceutical company focused on pioneering gene therapy treatments for genetically defined cardiovascular and central nervous system diseases. The company's innovative approach aims to address the underlying genetic causes of these debilitating conditions, offering the potential for long-term therapeutic benefit. Lexeo Therapeutics utilizes advanced adeno-associated virus (AAV) vector technology to deliver functional genes directly to target cells, restoring normal cellular function and mitigating disease progression. By focusing on precision medicine, Lexeo is striving to develop transformative therapies that improve the lives of patients suffering from serious genetic disorders, contributing to advancements in the fields of cardiology and neurology. The company's research and development efforts are geared towards creating a pipeline of novel gene therapies with the potential to address unmet medical needs.